Aardvark Therapeutics Financials

Aardvark Therapeutics (AARD) reported $5.1M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Aardvark Therapeutics (AARD) reported a net income of -$57.6M in fiscal year 2025, with a net profit margin of -1120.7%.

Aardvark Therapeutics (AARD) reported diluted earnings per share of $-2.93 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aardvark Therapeutics (AARD) had EBITDA of -$62.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Aardvark Therapeutics (AARD) had an operating margin of -1220.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Aardvark Therapeutics (AARD) had a net profit margin of -1120.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Aardvark Therapeutics (AARD) has a return on equity of -54.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Aardvark Therapeutics (AARD) generated -$54.3M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Aardvark Therapeutics (AARD) generated -$54.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Aardvark Therapeutics (AARD) had $117.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Aardvark Therapeutics (AARD) invested $95K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Aardvark Therapeutics (AARD) invested $48.9M in research and development during fiscal year 2025.

Aardvark Therapeutics (AARD) had 22M shares outstanding as of fiscal year 2025.

Aardvark Therapeutics (AARD) had a current ratio of 10.61 as of fiscal year 2025, which is generally considered healthy.

Aardvark Therapeutics (AARD) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Aardvark Therapeutics (AARD) had a return on assets of -49.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Aardvark Therapeutics (AARD) had $47.1M in cash against an annual operating cash burn of $54.2M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Aardvark Therapeutics (AARD) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Aardvark Therapeutics (AARD) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.